Capital participated in the initial $32 million Series B
and subsequent $60 million Series C financings of Aerovance,
Inc., a spin-out from Bayer Pharmaceuticals.
Aerovance is a biotherapeutics company focused on developing
and commercializing products for novel targets in respiratory
and inflammatory diseases. The Company has four Phase IIa
clinical programs in development directed towards asthma,
chronic obstructive pulmonary disease (COPD), eczema, and
cystic fibrosis. Aerovance targets products with substantial
market potential, which fill significant unmet medical needs.
Aerovance is located in Berkley, CA
In 2006, NGN Capital led a $39 million Series A financing of Artisan Pharma, Inc., a spin-out from Asahi Kasei Pharma Corporation (AKP) of Japan. In November 2011, Artisan acquired all shares in Artisan Pharma, Inc., making it a wholly owned subsidiary. Artisan was renamed Asahi Kasei Pharma America Corp. (AKP America)
Artisan Pharma, is focused on developing and commercializing products in critical care and hospital-based markets. As part of the financing, AKP has licensed a late-stage clinical development biologic, ART-123, to Artisan. ART-123 is a novel, recombinant, soluble, human thrombomodulin being developed for the treatment of DIC (disseminated intravascular coagulation) in sepsis and DVT (deep vein thrombosis).
In November 2011, Artisan was acquired by Asahi Kasei Pharma.
Artisan is located in Waltham, MA
NGN Capital led a $7 million Series B financing of
BeneChill, Inc., an innovative medical device company
that is developing a device to deliver therapeutic hypothermia
to the brain.
BeneChill is developing non-invasive cooling technology
for treatment following ischemic stroke, cardiac arrest
or traumatic brain injury. Reducing brain temperature
is believed by medical experts to reduce damage to the
brain following such events. Relative to other cooling
technologies, BeneChill’s cooling technology can
be deployed earlier, cools more rapidly and is selective
to the brain.
Ken Abramowitz holds a seat
on the BeneChill board of directors.
BeneChill, Inc. is located in San Diego, CA.
Capital led the $20 million Series C/D and the $25 million
Series E financings of BioArray Solutions Ltd.
BioArray is a molecular diagnostics company that has developed
a novel chip-based assay system to serve the needs of medium
and larger clinical laboratories. The initial applications
are in the blood transfusion and organ transplant donor
matching areas. BioArray Solutions combines assay systems
that are extremely accurate in even the most complex biological
situations with low cost and scalability.
In August, 2008, BioArray Solutions was acquired by Immucor,
BioArray Solutions, Ltd. is located in Warren, NJ
Capital led the second tranche of an $18 million Series
EKOS Corporation has developed an intravascular catheter
platform using low energy ultrasound to enhance drug delivery
through EKOS infusion catheters. Initial applications are
in stroke and peripheral arterial occlusion (PAO) disease.
The company currently sells the EKOS catheter for use in
PAO and is in NIH sponsored clinical trials for embolic
stroke. Both the PAO market as well as the market for embolic
stroke represent large markets with significant unmet clinical
In July 2013, EKOS was acquired by BTG plc.
EKOS is located in Bothell, WA
Pharma (Nasdaq: HZNP)
Pharma is a specialty pharmaceutical company which was created
through a merger of Horizon Therapeutics and Nitec Pharma
(a previous NGN investment): The company focuses on the
development and commercialization of treatments for arthritis,
pain and inflammation and has two late stage products. Duexa
has been filed in the US, Lodotra successfully completed
a US Ph III trials and is already approved in several European
countries and marketed by Merck Serono. in Germany.
Dr. Peter Johann, Managing General Partner at NGN Capital
is a member of the Board of Directors of Horizon Pharma.
In July 2011, Horizon Pharma completed an initial public offering on the Nasdaq.
Horizon Pharma, Inc. is located in Northbrook, IL.
Therapeutics and Nitec Pharma Complete Merger and Combine
Pharmaceuticals, Inc. (AMEX:JAV)
Capital led a $32 million PIPE financing of Javelin Pharmaceuticals,
Javelin is a specialty pharmaceutical company focusing on
the growing pain management market with three late stage
products in Phase III clinical development or in the regulatory
filing process. One of these products, Dyloject®, the
first bolus injectable diclofenac formulation, has been
approved for sale in the UK. Javelin has submitted Dyloject
for European Marketing Authorization Application (MAA).
Dyloject™ is posed to fill the void created by the
stumbling of COX-2 inhibitors in both EU and US markets
with a non-selective COX inhibitor. Combined with its Phase
II / III PMI-150 (intranasal ketamine) and Rylomine™
(intranasal morphine) products, Javelin is building an exciting
franchise in the moderate-to-severe and breakthrough pain
In July, 2010, Javelin was acquired by Hospira, Inc.
Javelin Pharmaceuticals is located in New York, NY.
AG (FRANKFURT: JI4)
Capital led the € 15.5 million Series B second closing
following the € 31 million intial round, for a total
€ 46.5 million Series B financing of Jerini, AG. Jerini
went public in November, 2005.
Jerini is a late stage biopharmaceutical company that has
completed Phase III clinical trials of Icatibant for the
treatment of Hereditary Angioedema (HAE). HAE is a debilitating,
potentially life-threatening disease caused by attacks of
swelling in the face, throat, abdomen and other parts of
the body. Jerini is focused on the discovery, development
and commercialization of peptide derived (peptidomimetic)
and small molecule therapeutics and has a deep pipeline
of preclinical products from its Peptide-to-Drugs platform.
In August of 2008, Jerini was acquired by Shire Pharmaceuticals,
Jerini is located in Berlin, Germany.
Capital led a € 7.5 million Series B investment in
KIKA Medical, Inc.
KIKA offers the first fully integrated web-based clinical
trial data management platform utilizing novel software
architecture and advanced professional services. Kika’s
Eventa™ Suite allows the customer to seamlessly build,
operate, track, analyze and audit clinical studies with
novel data handling and evaluation capabilities. The system
has powerful monitoring & process controls and is fully
FDA 21 CFR Part 11 compliant. It generates substantial cost
and time savings for the customer. The company has a strong
customer base and worldwide clinical trial knowledge, having
supported more than 100 studies across 60 countries.
In December, 2010, KIKA was acquired by Merge Healthcare, Inc.
KIKA is located in Boston, MA.
Capital invested $8 million in a PIPE transaction in Micromet
Micromet, Inc. is a biopharmaceutical
company focusing on the development of novel, proprietary
antibody-based products for cancer, inflammatory and autoimmune
diseases. Two product candidates are currently in clinical
trials. Adecatumumab (MT 210), a recombinant human monoclonal
antibody, is being evaluated in Phase II clinical trials
for the treatment of patients with breast cancer and prostate
cancer. MT103 (MEDI-538), a BiTE® product candidate,
is being studied in a Phase I clinical trial for the treatment
of patients with non-Hodgkin’s lymphoma. Micromet
has established a drug development platform based on its
BiTE® technology, a unique, antibody-based format that
leverages the cytotoxic potential of T-cells, the most powerful
“killer cells” of the human immune system. Micromet
has established collaborations with MedImmune, Serono and
In March 2012, Micromet was acquired by Amgen.
Micromet is located in Bethesda, MD
Capital, in its first buyout, joined with The Carlyle Group
to acquire MultiPlan, the largest independent preferred
provider organization (PPO) in the U.S.
MultiPlan is the nation’s oldest and largest independent
PPO network offering nationwide access to more than 4,200
hospitals, 100,000 ancillary care facilities and 550,000
physicians and specialists. The company’s 2,000 clients
include large and mid-sized insurers, third-party administrators,
self-funded plans, HMOs and other entities that pay claims
on behalf of health plans.
PPOs, which are the most common type of health plan in the
U.S. today, offer a provider network and range of value-added
services to help employers and other health plan sponsors
manage the cost of medical claims. MultiPlan offers a full
range of medical cost management solutions to a blue-ribbon
list of clients, including the national PPO network, specialty
networks, negotiation services and electronic claim routing
In August 2010, MultiPlan was acquired by BC Partners and Silver Lake.
MultPlan is located in New York, NY.
|PIN Pharma, Inc.
NGN Capital led a $6.75M Series A financing of PIN Pharma, Inc.
PIN Pharma, Inc. has developed a novel class of immunotherapeutics predicated upon a unique mode of action which has utility in oncology and other indications. Its lead compound has demonstrated exceptional preclinical data and safety profile in a very aggressive triple negative breast cancer mouse model.
William Gedale, Senior Advisor of NGN Capital, and Dr. Ivica Cerina, Partner of NGN Capital, serve as chairman and member of the board of directors, respectively.
PIN Pharma, Inc. is located in New York, NY
Capital led a $36 million Series B financing of OptiScan
Biomedical Corporation, an innovative diagnostic equipment
OptiScan is focused on further developing and commercializing
its system for continuously measuring blood glucose and
other analytes in order to support tight glycemic control.
Tight glycemic control has been shown in various clinical
studies to improve outcomes for hospital patients in intensive
Kenneth S. Abramowitz, Managing General Partner of NGN
Capital, holds a seat on the board of directors.
OptiScan is based in Hayward, CA.
Medical Interventions, Inc. (NASDAQ: PMII)
NGN Capital co-led a $35 million Series B financing of
Power Medical Interventions, Inc. (PMI). PMI is focused
on developing and commercializing novel high technology
surgical stapling closure devices for operating room use.
Power Medical went public in October, 2007.
PMI holds more than two dozen U.S. patents covering the
pioneering use of computer-assisted, electrical powered
placement of surgical staples for wound closure. This
advanced minimally invasive staple technology significantly
improves the accuracy, speed and safety of gastrointestinal
and pulmonary surgical procedures, allowing surgeons to
more confidently close bowel and lung tissue. In the future,
these instruments will increasingly facilitate surgery
that would not be readily feasible with traditional, manual
stapling techniques, such as deep bowel surgery and per-oral
anastomoses for weight loss surgery. Additionally, PMI
possesses a rich pipeline of follow-on products. PMI launched
the product line in 2002 and is actively selling to surgeons.
In September, 2009, Power Medical was acquired by Covidien.
Power Medical Interventions, Inc. is located in Langhorne,
Pharmaceuticals AG (SWX:SANN)
NGN Capital led the Series B financing (€ 43 million)
and pre-IPO rounds of Santhera Pharmaceuticals AG. Santhera
went public in November, 2006.
Santhera is a late stage specialty pharmaceutical company
with a neuromuscular disease focus. Santhera is in Phase
III clinical development in the US and in the Marketing
Authorization Application process in Europe for idebenone
for the treatment of cardiomyopathy related to Friedreich’s
Ataxia. Additional indications for idebenone are in
Phase II, including Duchenne Muscular Dystrophy (DMD)
and Leber's Hereditary Optic Neuropathy (LHON).
Santhera has valuable pharma/biotech marketing/development
partnerships in Dyskinesia in Parkinson’s Disease,
Congenital Muscular Dystrophy (CMD), and in type II
Santhera Pharmaceuticals is located in Liestal, Switzerland.
NGN Capital led a $10 million Series D financing of
Sightline Technologies Ltd., an innovative medical device
company located in the Advanced Technology Center in
Haifa, Israel. Sightline is focused on commercializing
and further developing the FDA-cleared ColonoSight®
system, a colonoscope with a disposable ColonoSleeve®
tube and sheath, which is used for diagnosing and treating
abnormalities in the large intestine.
The company’s advanced disposable technology potentially
improves safety and speed relative to traditional colonoscopy
systems, while the protective sheath places a disposable
barrier between the patient, the scope, and the physician.
In March, 2006, Sightline was acquired by Stryker Corporation.
(Please see press release for
Sightline Technologies is located in Haifa, Israel.
Bone Innovations, Inc.
NGN Capital and 3i co-led a $42 million Series B financing
of Small Bone Innovations, Inc. (SBI).
SBI was the first company to focus purely on arthritis
and trauma in small bones and joints in the upper and
lower extremities (shoulder to fingertip and mid-calf
to the toe) and is executing a roll-up strategy in those
market segments. The company has a deep pipeline of
implants, fixation and tissue technology products which
will enable it to take advantage of the strong growth
in this niche of the orthopedics market.
Kenneth S. Abramowitz, Managing General Partners at
NGN Capital, serves as member of the board of directors.
SBI is headquartered in New York, NY.
Capital led a $16 million Series B financing round for Tigris
Tigris Pharmaceuticals develops therapeutic molecules for
use in oncology, with a focus on molecularly targeted and
pharmacogenomics-based research platforms. Their lead molecule
is AFP-464, aminoflavone 464. This molecule will be entering
Phase II clinical trials shortly and has already established
multiple biomarkers that will be used to implement a targeted
development strategy in such key market segments as triple
negative breast cancer, and pancreatic, ovarian, and renal
cell cancers. Tigris’ second compound, GGTI-2418 (geranylgeranyltransferase
inhibitor), is currently enrolling in Phase I clinical trials
in patients with a variety of solid tumors. Tigris’
third molecule, GFB-204 (growth factor binding selective inhibitor
of VEGFR and PDGFR), is completing IND enabling studies and
would then move to Phase I studies as a cancer therapeutic
in patients with a variety of solid tumors.
In September 2012, NGN sold its position in Tigris.
Tigris is located in Bonita Springs, FL.